Clinical trials: Pembrolizumab
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome
- Trial name
- NCT03063632
- Testing
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Adult, Soft Tissue Sarcoma, Child
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
The purpose of this study is to evaluate the safety, tolerability and efficacy of doxorubicin in combination with pembrolizumab in subjects with metastatic or unresectable soft tissue sarcoma.
- Trial name
- NCT03056001
- Testing
- Pembrolizumab, Doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Bone Sarcoma
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
- Trial name
- NCT02301039
- Testing
- Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 144 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
The purpose of this research study is to test if Axitinib together with Pembrolizumab can slow tumor growth and know the side effects of the combination treatment.
- Trial name
- NCT02636725
- Testing
- Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonathan Trent, MD, PhD
Merkel Cell Carcinoma
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC).
- Trial name
- NCT03783078
- Testing
- Pembrolizumab (MK-3475)
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin Lymphoma
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma.
- Trial name
- NCT03179917
- Testing
- Pembrolizumab, Involved Site Radiation Therapy
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced).
- Trial name
- NCT04171219
- Testing
- Pembrolizumab, Talabostat Mesylate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia
- Trial name
- NCT03769467
- Testing
- Tabelecleucel, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Atara Biotherapeutics
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital